ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Type 2N von Willebrand Disease (VWD2N): Is it Always a Recessive Trait?

A.I. Woods1, L. Rossetti2, J. Paiva3, M.L. Romero3, A.N. Blanco3, M.M. Casinelli3, C. De Brasi2,4, A. Sanchez-Luceros1,3

1IMEX-CONICET-Academia Nacional de Medicina, Laboratorio de Hemostasia y Trombosis, Caba, Argentina, 2IMEX-CONICET-Academia Nacional de Medicina, Laboratorio de Genetica Molecular de la Hemofilia, Caba, Argentina, 3Instituto de Investigaciones Hematologicas, Academia Nacional de Medicina, Hemostasia y Trombosis, Caba, Argentina, 4Instituto de Investigaciones Hematologicas, Academia Nacional de Medicina, Laboratorio de Genetica Molecular de la Hemofilia, Caba, Argentina

Abstract Number: PB1585

Meeting: ISTH 2020 Congress

Theme: Platelet Disorders and von Willebrand Disease » VWF and von Willebrand Factor Disorders - Clinical Conditions

Background: VWD2N is a rare form of VWD, described as a recessive disease due to disease-causing variant (DCV) in homozygous or double/compound-heterozygous state. Heterozygotes individuals are considered carriers, and mostly asymptomatic; those homozygotes and double/compound-heterozygotes have clinical manifestations and laboratory phenotype frequently mistaken for those of mild hemophilia A.

Aims: To show the variable inheritance of VWD2N according to the DCV in a selected group of patients phenotypic and genotypically diagnosed.

Methods: We studied the F8 in five symptomatic patients with heterozygous DCV in VWF associated to VWD2N (Table 1). The severity of bleeding symptoms was evaluated by the ISTH/SSC bleeding assessment tool (ISTH/SSC BAT).
Patients were studied after signing the written-informed consent. The study was approved by local Ethics Committee.
Laboratory tests: FVIII:C (one-stage method), VWF:Ag (ELISA), VWF:RCo (aggregometry). Mixing studies of the patient/control plasmas to evaluate the presence of inhibitors were undertaken by APTT and VWF:RCo. FVIII:C/VWF:Ag (normal value [nv]>0.8) and VWF:RCo/VWF:Ag (nv>0.6) were calculated in each patient.
Genomic DNA was extracted from peripheral blood. Exons 17-27 of the VWF and all 26 exons of F8 were PCR-amplified and directly sequenced (Sanger method). F8 exons were previously heteroduplex-analysed by conformation sensitive gel electrophoresis.

Results: Both normal VWF:Ag and VWF:RCo levels, and normal VWF:RCo/VWF:Ag were observed in all patients. No DCV were observed in F8 (Table 1).
Patients with p.Arg816Trp had very low FVIII (< 12 IU/dL) and FVIII/VWF:Ag< 0.11, abnormal BAT; 2 out of 3 patients had major bleeding episodes.
Patients with p.Arg854Gln had low FVIII levels (40-45 IU/dL) and FVIII/VWF:Ag< 0.7, and abnormal BAT. One patient had a major bleeding episode.

Conclusions: According to the FVIII levels and FVIII/VWF:Ag values of the patients, heterozygous p.Arg816Trp appears to cause a clearly dominant VWD2N.
Patients with p.Arg854Gln should be considered as VWD2N in spite of their heterozygous state in VWF given their bleeding tendency.

Patient Gender/age DCV in VWF DCV in F8 FVIII VWF:Ag FVIII/VWF:Ag BAT Major bleeding
VJM Female/63 p.Arg816Trp none 12 110 0.11 15 yes
BS Male/4 p.Arg816Trp none 8 73 0.11 6 yes
BN Female/2 p.Arg816Trp none 4 76 0.05 2 no
RC Female/11 p.Arg854Gln none 45 72 0.63 7 yes
BMC Female/16 p.Arg854Gln none 40 82 0.49 3 no

[Table 1: Phenotypic and genotypic parameters in patients with VWD2N.]

To cite this abstract in AMA style:

Woods AI, Rossetti L, Paiva J, Romero ML, Blanco AN, Casinelli MM, De Brasi C, Sanchez-Luceros A. Type 2N von Willebrand Disease (VWD2N): Is it Always a Recessive Trait? [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/type-2n-von-willebrand-disease-vwd2n-is-it-always-a-recessive-trait/. Accessed October 1, 2023.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/type-2n-von-willebrand-disease-vwd2n-is-it-always-a-recessive-trait/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress ยป

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley